{
    "id": "dbpedia_2267_1",
    "rank": 49,
    "data": {
        "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/",
        "read_more_link": "",
        "language": "en",
        "title": "Identification of a Potent Phosphoinositide 3‐Kinase Pan Inhibitor Displaying a Strategic Carboxylic Acid Group and Development of Its Prodrugs",
        "top_image": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0",
        "meta_img": "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-card-share.jpg?_=0",
        "images": [
            "https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png",
            "https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg",
            "https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg",
            "https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg",
            "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/logo-blackwellopen.png",
            "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/corrauth.gif",
            "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/corrauth.gif",
            "https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/corrauth.gif",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g001.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g002.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g003.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g004.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g011.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g012.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g013.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g005.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g014.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g015.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g006.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g007.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g008.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g009.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g010.jpg",
            "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/bin/CMDC-12-1542-g016.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [
            "Prof. Tracey Pirali",
            "Dr. Elisa Ciraolo",
            "Dr. Silvio Aprile",
            "Dr. Alberto Massarotti",
            "Dr. Alex Berndt",
            "Dr. Alessia Griglio",
            "Dr. Marta Serafini",
            "Dr. Valentina Mercalli",
            "Dr. Clarissa Landoni",
            "Dr. Carlo Cosimo Campa"
        ],
        "publish_date": "2017-09-21T00:00:00",
        "summary": "",
        "meta_description": "Activation of the phosphoinositide 3‐kinase (PI3K) pathway is a key signaling event in cancer, inflammation, and other proliferative diseases. PI3K inhibitors are already approved for some specific clinical indications, but their systemic on‐target ...",
        "meta_lang": "en",
        "meta_favicon": "https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/favicons/favicon.ico",
        "meta_site_name": "PubMed Central (PMC)",
        "canonical_link": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697638/",
        "text": "Synthesis\n\n5‐[Bis(Methylthio)methylene]‐2,2‐dimethyl‐1,3‐dioxane‐4,6‐dione (16): TEA (48.0 mL, 0.346 mmol) and CS2 (10.2 mL, 0.17 mmol) were added to a solution of Meldrum's acid (25.0 g, 0.17 mmol) in DMSO (300 mL). The mixture was stirred for 3 h at room temperature, and then iodomethane (2 equiv) was slowly added at 0 °C. The mixture was stirred overnight at room temperature. Ice was added to the flask to promote precipitation of the product, which was then filtered to yield compound 16 as a yellow solid (34.1 g, 81 %).\n\n5‐[(2‐Iodophenylamino)(methylthio)methylene]‐2,2‐dimethyl‐1,3‐dioxane‐4,6‐dione (18): A mixture of 5‐[bis(methylthio)methylene]‐2,2‐dimethyl‐1,3‐dioxane‐4,6‐dione (453 mg, 1.83 mmol) and 2‐iodoaniline (400 mg, 1.83 mmol) in ethanol (4 mL) was heated at 80 °C for 4 h. During the reaction, the product precipitated. Filtration yielded 18 as a yellow solid (522 mg, 68 %).\n\n5‐[(2‐Iodophenylamino)(morpholino)methylene]‐2,2‐dimethyl‐1,3‐dioxane‐4,6‐dione (20): A mixture of 5‐[(2‐iodophenylamino)(methylthio) methylene]‐2,2‐dimethyl‐1,3‐dioxane‐4,6‐dione (500 mg, 1.23 mmol) and morpholine (214 μL, 2.46 mmol) in THF (5 mL) was heated at reflux overnight. The volatiles were evaporated under reduced pressure. Diethyl ether (10 mL) was added, and the solid was filtered and washed with EtOAc (10 mL) to give 20 as a white powder (429 mg, 76 %).\n\n8‐Iodo‐2‐morpholinoquinolin‐4(1H)‐one (21): 5‐[(2‐Iodophenylamino)(morpholino)methylene]‐2,2‐dimethyl‐1,3‐dioxane‐4,6‐dione (1 g, 2.18 mmol) was heated in diphenyl ether (10 mL) at reflux for 30 min. The crude brown oil, after purification by column chromatography (petroleum ether/EtOAc 5:5 to 0:1), yielded 21 as a white powder (519 mg, 67 %).\n\n2‐Morpholino‐8‐[(trimethylsilyl)ethynyl] quinolin‐4(1H)‐one (22): Under a nitrogen atmosphere, PdCl2(PPh3)2 (6 mg, 0.00843 mmol), CuI (5 mg, 0.0252 mmol), DIPEA (48 μL, 0.280 mmol), and trimethylsilylacetylene (39 μL, 0.280 mmol) were added to a solution of 8‐iodo‐2‐morpholinoquinolin‐4(1H)‐one (100 mg, 0.280 mmol) in toluene (2 mL) and DMF (two drops). The mixture was stirred at room temperature for 2 h. The mixture was diluted with water (10 mL) and extracted with EtOAc (5×10 mL). The combined organic layer was dried with sodium sulfate. The crude material was purified by column chromatography (EtOAc/MeOH 1:0 to 95:5) to yield 22 as a yellow solid (66 mg, 72 %).\n\n8‐Ethynyl‐2‐morpholinoquinolin‐4(1H)‐one (12): Potassium carbonate (949 mg, 6.88 mmol) was added to a solution of 2‐morpholino‐8‐[(trimethylsilyl)ethynyl]quinolin‐4(1H)‐one (1.87 g, 5.74 mmol) in methanol (20 mL). The mixture was stirred at room temperature for 3 h. The volatiles were removed in vacuo. The mixture was diluted with brine (20 mL) and extracted with CH2Cl2 (4×10 mL). The combined organic layer was dried with sodium sulfate. The crude material was purified by column chromatography (EtOAc/MeOH 1:0 to 9:1) to yield 12 as a yellow solid (1.23 g, 84 %).\n\n4‐Morpholino‐4H‐pyrrolo[3,2,1‐ij]quinolin‐6(5H)‐one (24): Alkyne 12 (78 mg, 0.31 mmol) was added to a suspension of phenyl azide (23; 100 mg, 0.31 mmol) in water (570 μL) and tBuOH (570 μL). Then, 1 m aqueous sodium ascorbate (29 μL) and copper sulfate pentahydrate (0.72 mg, 0.29 mmol) were added under vigorous stirring. The product precipitated, and it was filtered and washed with water (2×5 mL) and diethyl ether (2×5 mL) to give 24 as a yellow solid (49 mg, 62 %).\n\nGeneral procedure for the synthesis of compounds 25–54: TBTA (0.0040 mmol, 0.05 equiv) was added to a solution of Cu(OAc)2 (0.0040 mmol, 0.05 equiv) in THF (0.3 mL), and the resulting mixture was stirred at room temperature for 30 min. A solution of azide 13 (0.079 mmol, 1 equiv) in THF (0.3 mL), a solution of alkyne 12 (0.079 mmol, 1 equiv) in THF (0.3 mL), and a solution of sodium ascorbate (0.0079 mmol, 0.1 equiv) in a minimum amount of water were added. The mixture was stirred at room temperature overnight. The product precipitated, and it was filtered and washed with water (2×5 mL) and diethyl ether (2×5 mL) to give a solid. The crude product was then screened, and compounds 25, 35, 37, 45, 48, and 54 were resynthesized and subjected to column chromatography (EtOAc and EtOAc/MeOH 9:1).\n\n2‐Morpholino‐8‐(1‐phenyl‐1H‐1,2,3‐triazol‐4‐yl)quinolin‐4(1H)‐one (25): Yellow solid (90 %): mp: 244–245 °C (dec.); 1H NMR (300 MHz, [D6]DMSO): δ=9.30 (s, 1 H), 8.39 (br s, 1 H), 7.96–7.91 (m, 4 H), 7.63 (t, J=7.7 Hz, 2 H), 7.49 (t, J=7.7 Hz, 1 H), 7.30 (t, J=7.7 Hz, 1 H), 6.51 (s, 1 H), 3.79–3.73 (m, 4 H), 3.59–3.53 ppm (m, 4 H); 13C NMR (75 MHz, [D6]DMSO): δ=160.7, 152.8, 137.3, 136.4, 131.1, 130.6 (2C), 129.2, 128.7, 126.3, 124.3, 121.9, 121.7, 120.6, 91.8, 66.5, 46.4 ppm; IR (KBr): ν˜ =ν˜ 3437, 3122, 1636, 1584, 1500, 1237, 1124, 795, 761, 688 cm−1; MS (ESI): m/z=374 [M+H]+; elemental analysis calcd (%) for C21H19N5O2 (373.41): C 67.55, H 5.13, N 18.76; found: C 67.71, H 5.25, N 18.60.\n\n8‐[1‐(3‐Hydroxyphenyl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (26): Yellow solid (90 %).\n\n8‐[1‐(3‐Hydroxy‐4‐methoxyphenyl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (27): Yellow solid (40 %).\n\n8‐[1‐(4‐Chlorophenyl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (28): Gray solid (50 %).\n\n2‐Morpholino‐8‐{1‐[4‐(trifluoromethoxy)phenyl]‐1H‐1,2,3‐triazol‐4‐yl}quinolin‐4(1H)‐one (29): Yellow solid (69 %).\n\n8‐[1‐(4‐Methoxy‐3‐nitrophenyl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (30): Yellow solid (50 %).\n\nMethyl‐4‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (31): Gray solid (90 %).\n\n8‐[1‐(4‐Aminophenyl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (32): Brown solid (65 %).\n\n2‐{4‐[4‐(2‐Morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]phenyl} acetonitrile (33): Yellow solid (74 %).\n\n2‐Morpholino‐8‐[1‐(naphthalen‐2‐yl)‐1H‐1,2,3‐triazol‐4‐yl]quinolin‐4(1H)‐one (34): Yellow solid (68 %).\n\n8‐[1‐(3‐Methoxyphenyl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (35): Yellow solid (57 %): mp: 141–142 °C (dec.); 1H NMR (300 MHz, CD3OD): δ=9.03 (s, 1 H), 8.08 (d, J=7.7 Hz, 1 H), 7.92 (d, J=7.7 Hz, 1 H), 7.47–7.45 (m, 3 H), 7.26 (t, J=7.7 Hz, 1 H), 7.08–7.04 (m, 1 H), 5.79 (s, 1 H), 3.89 (s, 3 H), 3.84 (t, J=4.9 Hz, 4 H), 3.49 ppm (t, J=4.9 Hz, 4 H); 13C NMR (75 MHz, [D6]DMSO): δ=160.8, 138.4, 134.5, 133.8, 132.6 (2 C), 131.5, 128.7, 123.1, 121.6, 121.2, 115.2, 113.6, 112.5, 110.9, 106.0, 92.1, 66.5, 56.1, 45.7 ppm; IR (KBr): ν˜ =3263, 2965, 1622, 1583, 1495, 1235, 1123, 1003, 871, 791 cm−1; MS (ESI): m/z=404 [M+H]+; elemental analysis calcd (%) for C22H21N5O3 (403.43): C 65.50, H 5.25, N 17.36; found: C 65.22, H 5.27, N 17.33.\n\n2‐Morpholino‐8‐[1‐(quinolin‐3‐yl)‐1H‐1,2,3‐triazol‐4‐yl]quinolin‐4(1H)‐one (36): Yellow solid (93 %).\n\n3‐{[4‐(2‐Morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoic acid (37): Yellow solid (70 %): mp: 290–291 °C (dec.); 1H NMR (300 MHz, [D6]DMSO): δ=8.08 (s, 1 H), 8.00 (d, J=7.7 Hz, 1 H), 7.93 (d, J=3.3 Hz, 1 H), 7.88 (d, J=7.7 Hz, 1 H), 7.51 (t, J=7.7 Hz, 1 H), 7.34–7.29 (m, 2 H), 7.02 (d, J=3.3 Hz, 1 H), 6.50 (s, 1 H), 5.75 (s, 2 H), 3.85–3.81 (m, 4 H), 3.26–3.24 ppm (m, 4 H); 13C NMR (75 MHz, [D6]DMSO): δ=162.4, 159.6, 145.1, 136.2, 134.5, 133.6, 133.1, 130.2, 130.0, 128.2, 126.0, 125.6, 125.2, 122.3, 121.5, 121.2, 118.3, 91.9, 66.5, 53.2, 45.8 ppm; IR (KBr): ν˜ =2970, 2866, 1707, 1636, 1582, 1444, 1242, 1117, 789, 739 cm−1; MS (ESI): m/z=432 [M+H]+; elemental analysis calcd (%) for C23H21N5O4 (431.44): C 64.03, H 4.91, N 16.23; found: C 64.00, H 4.98, N 16.20.\n\nN ‐{4‐Methoxy‐3‐[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]phenyl}acetamide (38): Yellow solid (78 %).\n\n8‐{1‐[3‐Methoxy‐5‐(trifluoromethoxy)phenyl]‐1H‐1,2,3‐triazol‐4‐yl}‐2‐morpholinoquinolin‐4(1H)‐one (39): Yellow solid (90 %).\n\n8‐[1‐(4‐Hydroxy‐2‐methylphenyl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (40): Brown solid (31 %).\n\n8‐{1‐[2‐(Hydroxymethyl)phenyl]‐1H‐1,2,3‐triazol‐4‐yl}‐2‐morpholinoquinolin‐4(1H)‐one (41): Yellow solid (40 %).\n\nMethyl 4‐[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]benzoate (42): Yellow solid (90 %).\n\n8‐[1‐(3,4‐Dimethoxyphenyl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (43): Gray amorphous solid (76 %).\n\n8‐[1‐(4‐Methoxyphenyl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (44): Light‐yellow solid (55 %).\n\n4‐[4‐(2‐Morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]benzoic acid (45): Yellow solid (66 %): mp: 269–270 °C (dec.); 1H NMR (300 MHz, [D6]DMSO): δ=9.39 (s, 1 H), 8.42 (d, J=6.9 Hz, 2 H), 8.11–8.09 (m, 2 H), 7.97 (d, J=6.9 Hz, 2 H), 7.33 (t, J=8.2 Hz, 1 H), 6.54 (s, 1 H), 3.79–3.77 (m, 4 H), 3.60–3.58 ppm (m, 4 H); 13C NMR (75 MHz, [D6]DMSO): δ=161.3, 159.8, 138.2, 136.2, 133.3, 132.6, 131.7, 131.4, 128.7, 126.4, 124.1, 123.8, 121.2, 120.6, 111.8, 92.0, 66.3, 46.3 ppm; IR (KBr): ν˜ =3336, 3128, 1697, 1620, 1585, 1414, 1238, 811, 768, 750 cm−1; MS (ESI): m/z=418 [M+H]+; elemental analysis calcd (%) for C22H19N5O4 (417.42): C 63.30, H 4.59, N 16.78; found: C 63.62, H 4.95, N 16.48.\n\n8‐[1‐(Benzo[d][1,3]dioxol‐5‐yl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (46): Yellow solid (91 %).\n\n8‐[1‐(3,5‐Dimethoxyphenyl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (47): Yellow solid (84 %).\n\n8‐(1‐Benzyl‐1H‐1,2,3‐triazol‐4‐yl)‐2‐morpholinoquinolin‐4(1H)‐one (48): Light‐yellow solid (84 %): mp: 90–91 °C; 1H NMR (300 MHz, CD3OD): δ=8.57 (s, 1 H), 8.03 (d, J=7.7 Hz, 1 H), 7.83 (d, J=7.7 Hz, 1 H), 7.42–7.38 (m, 5 H), 7.24 (t, J=7.7 Hz, 1 H), 5.81 (s, 1 H), 5.68 (s, 2 H), 3.88–3.85 (m, 4 H), 3.53–3.50 ppm (m, 4 H); 13C NMR (75 MHz, [D6]DMSO): δ=160.2, 145.2, 136.5, 131.8, 130.4, 129.4, 129.0, 128.2, 127.4, 127.3, 125.1, 122.3, 121.6, 118.6, 91.9, 66.5, 53.6, 45.8 ppm; IR (KBr): ν˜ =3264, 3142, 1628, 1586, 1501, 1445, 1255, 1117, 785, 728 cm−1; MS (ESI): m/z=388 [M+H]+; elemental analysis calcd (%) for C22H21N5O2 (387.43): C 68.20, H 5.46, N 18.08; found: C 68.18, H 5.72, N 17.83.\n\nMethyl 3‐[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]benzoate (49): Yellow solid (62 %).\n\n4‐[4‐(2‐Morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]benzenesulfonamide (50): Yellow solid (95 %).\n\n8‐[1‐(2‐Methoxyphenyl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (51): Yellow amorphous solid (90 %).\n\n3‐[4‐(2‐Morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]benzoic acid (52): Yellow solid (89 %).\n\n2‐Morpholino‐8‐[1‐(naphthalen‐1‐yl)‐1H‐1,2,3‐triazol‐4‐yl]quinolin‐4(1H)‐one (53): Yellow solid (90 %).\n\n8‐[1‐(2‐Hydroxyphenyl)‐1H‐1,2,3‐triazol‐4‐yl]‐2‐morpholinoquinolin‐4(1H)‐one (54): Brown solid (77 %): mp: 253–254 °C (dec.); 1H NMR (300 MHz, [D6]DMSO): δ=9.38 (s, 1 H), 8.43 (br s, 1 H), 7.94 (d, J=7.7 Hz, 1 H), 7.78 (d, J=7.1 Hz, 1 H), 7.31–7.26 (m, 3 H), 7.15 (d, J=7.7 Hz, 1 H), 7.00 (t, J=7.7 Hz, 1 H), 6.55 (s, 1 H), 3.76–3.74 (m, 4 H), 3.56–3.54 ppm (m, 4 H); 13C NMR (75 MHz, [D6]DMSO): δ=159.5, 154.8, 149.4, 145.2, 141.3, 130.1, 128.3, 127.0, 126.0, 125.2, 124.7, 121.6, 120.3, 117.9, 109.9, 101.3, 92.0, 66.6, 51.9 ppm; IR (KBr): ν˜ =3230, 2949, 1632, 1586, 1236, 1123, 800, 750 cm−1; MS (ESI): m/z=390 [M+H]+; elemental analysis calcd (%) for C21H19N5O3 (389.41): C 64.77, H 4.92, N 17.98; found: C 64.88, H 5.17, N 18.21.\n\n4‐[4‐(2‐Morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]butanoic acid (55): Yellow solid (47 %).\n\n5‐[4‐(2‐Morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]pentanoic acid (56): Yellow solid (40 %).\n\n6‐84‐(2‐Morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]hexanoic acid (57): Yellow solid (48 %).\n\nN ‐(Methylsulfonyl)‐3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzamide (58): Yellow solid (69 %).\n\n3‐{[4‐(2‐Morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzamide (59): Yellow solid (95 %).\n\nN ‐Benzyl‐3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzamide (60): Yellow solid (24 %).\n\nN ‐Cyclopropyl‐3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzamide (61): Yellow solid (31 %).\n\nN,N ‐Diethyl‐3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzamide (62): Yellow solid (40 %).\n\n8‐{1‐[3‐(1H‐Tetrazol‐5‐yl)benzyl]‐1H‐1,2,3‐triazol‐4‐yl}‐2‐morpholinoquinolin‐4(1H)‐one (63): 3‐{[4‐(2‐Morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzonitrile was prepared following the general procedure for the click reaction. Yellow solid (95 %). 1H NMR (300 MHz, [D6]DMSO): δ=8.75 (s, 1 H), 8.36 (d, J=7.1 Hz, 1 H), 7.92 (s, 1 H), 7.86 (m, 2 H), 7.74 (d, J=7.1 Hz, 1 H), 7.63 (t, J=7.1 Hz, 1 H), 7.28 (t, J=7.3 Hz, 1 H), 6.49 (s, 1 H), 5.80 (s, 2 H), 3.74–3.70 (m, 4 H), 3.47–3.41 ppm (m, 4 H); MS (ESI): m/z=413 [M+H]+.\n\nSodium azide (46.8 mg, 0.72 mmol) was added to a solution of 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzonitrile (200.0 mg, 0.48 mmol) in DMF (1.2 mL) and methanol (1.2 mL). The mixture was stirred at 110 °C overnight. Diethyl ether (3 mL) was added to the mixture, and the product precipitated. It was filtered to yield 63 as a brown solid (214 mg, 98 %).\n\nGeneral procedure for the synthesis of ester prodrugs 64–76: TBTA (0.0040 mmol, 0.05 equiv) was added to a solution of Cu(OAc)2 (0.0040 mmol, 0.05 equiv) in THF (0.3 mL), and the resulting mixture was stirred at room temperature for 30 min. A solution of the azide (0.079 mmol, 1 equiv) in THF (0.3 mL), a solution of alkyne 12 (0.079 mmol, 1 equiv) in THF (0.3 mL), and a solution of sodium ascorbate (0.0079 mmol, 0.1 equiv) in a minimum amount of water were added. The mixture was stirred at room temperature overnight. The product precipitated, and it was filtered and washed with water (2×5 mL) and diethyl ether (2×5 mL) to give a solid. The crude product was subjected to column chromatography (EtOAc and EtOAc/MeOH 9:1).\n\nMethyl 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (64): White solid (95 %): mp: 185.5–186.5 °C; 1H NMR (300 MHz, [D6]DMSO): δ=8.72 (s, 1 H), 8.37 (d, J=7.7 Hz, 1 H), 8.02 (s, 1 H), 7.97–7.90 (m, 2 H), 7.71 (d, J=7.7 Hz, 1 H), 7.59 (t, J=7.7 Hz, 1 H), 7.28 (t, J=7.9 Hz, 1 H), 6.47 (s, 1 H), 5.82 (s, 2 H), 3.85 (s, 3 H), 3.74–3.63 (m, 4 H), 3.58–3.24 ppm (m, 4 H); 13C NMR (75 MHz, CDCl3): δ=166.3, 147.7, 134.4, 132.7, 131.5, 130.4, 129.8, 129.7, 129.5, 128.7, 126.4, 123.3, 122.4, 120.8, 118.9, 91.9, 66.3, 54.4, 52.5, 46.3 ppm; IR (KBr): ν˜ =3422, 1720, 1582, 1287, 1130, 732 cm−1; MS (ESI): m/z=446 [M+H]+; elemental analysis calcd (%) for C24H23N5O4 (445.47): C 64.71, H 5.20, N 15.72; found: C 64.31, H 5.47, N 15.70.\n\nBenzyl 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (65): White solid (99 %).\n\nIsopropyl 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (66): Yellow solid (52 %).\n\nEthyl 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (67): White solid (64 %).\n\nButyl 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (68): Yellow solid (66 %).\n\ntert ‐Butyl 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (69): Yellow solid (28 %).\n\nPyridin‐4‐ylmethyl 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (70): Yellow solid (79 %).\n\n2‐Morpholinoethyl 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (71): Yellow solid (45 %).\n\nBenzo[d][1,3]dioxol‐5‐yl methyl 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (72): Yellow solid (72 %).\n\nIsopentyl 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (73): Yellow solid (78 %).\n\nPentan‐2‐yl 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (74): Yellow solid (63 %).\n\nUndecyl 3‐{[4‐(2‐morpholino‐4‐oxo‐1,4‐dihydroquinolin‐8‐yl)‐1H‐1,2,3‐triazol‐1‐yl]methyl}benzoate (75): White solid (58 %)."
    }
}